Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
The board of GenVec Inc. has voted to liquidate and dissolve the struggling Gaithersburg biotech, it announced Tuesday in a securities filing. The move follows a string of setbacks for GenVec, which three years ago saw its lead pancreatic cancer drug candidate, TNFerade, fail in late-stage trials. In 2011, longtime CEO Paul Fischer announced his retirement from the company. GenVec posted a net loss for 2012 of $14.1 million, almost twice the amount from the year before.
Help employers find you! Check out all the jobs and post your resume.
